Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability.
Massimino M, Stella S, Tirrò E, Pennisi MS, Stagno F, Vitale SR, Romano C, Tomarchio C, Parrinello NL, Manzella L, Di Raimondo F, Vigneri P. Massimino M, et al. Among authors: vigneri p. Onco Targets Ther. 2023 Oct 3;16:803-816. doi: 10.2147/OTT.S413825. eCollection 2023. Onco Targets Ther. 2023. PMID: 37807980 Free PMC article.
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P. Massimino M, et al. Among authors: vigneri p. Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20. Carcinogenesis. 2014. PMID: 24445143
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia.
Manzella L, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Vitale SR, Vigneri P. Manzella L, et al. Among authors: vigneri p. Curr Cancer Drug Targets. 2016;16(7):594-605. doi: 10.2174/1568009616666160105105857. Curr Cancer Drug Targets. 2016. PMID: 26728039 Review.
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. Pennisi MS, et al. Among authors: vigneri p. Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019. Front Oncol. 2019. PMID: 31456947 Free PMC article.
171 results